Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.
View stock
VS
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
View stock

Stock highlights

Stock comparison highlights
Stock name
Neumora TherapeuticsEli Lilly
Last price
$0.50$1,354.00
Currency
USD
USD
$95M$1.2T
-43.94
-$1.22$30.81
2.780.39
0$6.69
00.51%
Sector
HealthHealth
Employees
6350,000
Ticker
$NMRA$LLY
Primary listing
NASDAQNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in $NMRA or $LLY on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.